Ryan Smith, DO
Psychiatry · Eastport, MENPI 1245541721
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,872 of the $92,216 with a category attached, or 79.0%. 6 manufacturers reported payments, led by Alkermes, Inc. at 46.4% of the total. Reporting peaked in 2022 at $40,145 and has fallen 67.6% since, to $13,016 in 2025. Among psychiatry clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $490.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$43K
- Otsuka America Pharmaceutical, Inc.$34K
- Axsome Therapeutics, Inc.$13K
- Johnson & Johnson$2K
- AbbVie$308
- Otsuka Pharmaceutical Development & Commercialization, Inc.$203
Across 2 payments — averaging $1738.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$3K
What the payments were for
- Consulting fees$7,2458%
- Speaking & faculty fees$72,87279%
- Travel & lodging$7,1098%
- Food & beverage$4,9895%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 59 | $42,806 |
| Otsuka America Pharmaceutical, Inc. | 66 | $34,322 |
| Axsome Therapeutics, Inc. | 13 | $13,016 |
| Johnson & Johnson | 43 | $1,560 |
| AbbVie(2 entities) | 5 | $308 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $203 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$104,158
- ARISTADA$67,456
- ABILIFY MAINTENA$33,535
- Symbravo$12,650
- ARISTADA INITIO$6,482
- ABILIFY ASIMTUFII$2,106
- SPRAVATO$466
- ABILIFY MYCITE$175
- BOTOX$117
How this compares
$92,216 in reported general payments places this provider in the 95th percentile of 167 psychiatry providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Eastport
- Edward BilottiSouth Portland$88K
- Ira ScottBangor$27K
- Charmaine PatelBangor$17K
- Glenn CurrierPortland$8K
- Elliot GruenLewiston$7K
- David JonesArundel$5K
- Christine WhitePrinceton$2K
- Sally WeissBangor$2K
- Kenneth WhiteVinalhaven$2K
- Michael PatnaudeWestbrook$979
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.